Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from QuantumPharm, Inc. ( (HK:2228) ) is now available.
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, announced its interim financial results for the first half of 2025, reporting a significant revenue increase of 403.8% year-on-year to RMB517.1 million. The company achieved profitability for the first time on a half-year basis with an adjusted net profit of RMB141.6 million, marking a milestone in its growth trajectory. XtalPi’s business development was bolstered by a major collaboration with DoveTree Medicines LLC, contributing to a 615.2% surge in revenue from its drug discovery solutions business. The collaboration, which includes an initial payment of US$51 million and potential future payments, highlights the global recognition of XtalPi’s AI and robotics drug discovery platform.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
Average Trading Volume: 155,109,186
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$41.55B
See more insights into 2228 stock on TipRanks’ Stock Analysis page.